Latest From Chiasma Inc.
The latest drug development news and highlights from our US FDA Performance Tracker.
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Chiasma has bounced back from a 2016 CRL for Mycapssa with a new SPA-agreed Phase III trial meeting all its primary and secondary endpoints. The product is positioned to be the first oral treatment for acromegaly.
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Chiasma (Israel) Ltd.
- North America
- Parent & Subsidiaries
- Chiasma Inc.
- Senior Management
Raj Kannan, CEO
Asi Haviv, VP, Clin. Dev.
Dana Gelbaum, VP, Global Mktg. & Corp. Dev.
Mark J Fitzpatrick, Pres.
Drew Enamait, VP, Fin. & Admin.
- Contact Info
Phone: (972)(844) 304-2462
460 Totten Pond Rd., Ste. 530
Waltham, MA 02451
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.